{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:17:51Z","timestamp":1761164271626,"version":"build-2065373602"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3913,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>A 22\u2010year\u2010old man was hospitalized after unexplained seizure\u2010like activity and unresponsiveness. A urine toxicology screen was negative for salicylates, acetaminophen, alcohol, and drugs of abuse. Medical history was insignificant with the exception of recent (within 2 wks) ingestion of Hydroxycut, a dietary supplement purported to be energy enhancing, muscle building, and fat burning. The agent contains ephedra alkaloids and caffeine, which are both central nervous system stimulants; the etiology of seizure was attributed to their consumption. Due to a significant number of reported adverse events, the United States Food and Drug Administration (FDA) proposed regulations for dietary supplements containing ephedra alkaloids and requested an independent review of case reports linked to these products. Because herbal products are not subject to the same rigorous FDA regulations required for prescription and over\u2010the\u2010counter products, consumers unknowingly risk adverse effects when taking these products. Questioning patients about consumption of herbal products should be part of routine medical visits.<\/jats:p>","DOI":"10.1592\/phco.21.6.647.34542","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T06:25:36Z","timestamp":1086762336000},"page":"647-651","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Seizure Activity and Unresponsiveness after Hydroxycut Ingestion"],"prefix":"10.1002","volume":"21","author":[{"given":"Denise R.","family":"Kockler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle W.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy L.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199301283280406","article-title":"Unconventional medicine in the United States, prevalence, costs, and patterns of use","volume":"328","author":"Eisenberg D.M.","year":"1993","journal-title":"N Engl J Med"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.18.1569"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.9.877.35200"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19097"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.4.257.34886"},{"volume-title":"Illnesses and injuries associated with the use of selected dietary supplements","year":"2000","author":"U.S. Food and Drug Administration.","key":"e_1_2_1_7_2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","DOI":"10.1037\/e543712006-006","volume-title":"An FDA guide to dietary supplements","author":"Kurtzweil P.","year":"1998"},{"volume-title":"Hydroxycut product information","year":"2000","author":"Muscletech Research and Development, Inc.","key":"e_1_2_1_9_2"},{"volume-title":"The review of natural products","year":"1989","author":"DerMarderosian A.","key":"e_1_2_1_10_2"},{"key":"e_1_2_1_11_2","first-page":"689","article-title":"Adverse events associated with ephedrine\u2010containing products\u2014Texas, December 1993\u2010September 1995","volume":"45","author":"Centers for Disease Control and Prevention.","year":"1996","journal-title":"MMWR"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130321"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/ajhp\/54.14.1578","article-title":"FDA proposes constraints on ephedrine dietary supplements","volume":"54","author":"Anonymous.","year":"1997","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_14_2","first-page":"15","article-title":"New safety measures are proposed for dietary supplements containing ephedrine alkaloids","volume":"278","author":"Nightengale S.L.","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ajhp\/57.10.922","article-title":"FDA backs away from elements of plan to regulate ephedrine supplements","volume":"57","author":"Miller J.L.","year":"2000","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432502"},{"key":"e_1_2_1_17_2","first-page":"673","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Serafin W.E.","year":"1996"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549010-00004"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(92)90318-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17327"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.10.1560b"},{"key":"e_1_2_1_22_2","first-page":"1466","article-title":"Chromium picolinate","volume":"32","author":"Chavez M.L.","year":"1997","journal-title":"Hosp Pharm"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(95)90113-2"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(94)90120-1"},{"volume-title":"Carnitor (levocarnitine) package insert","year":"1999","author":"Sigma\u2010tau Pharmaceuticals, Inc.","key":"e_1_2_1_25_2"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.1.432"},{"volume-title":"The review of natural products","year":"2000","author":"DerMarderosian A.","key":"e_1_2_1_27_2"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.6.647.34542","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.6.647.34542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:31Z","timestamp":1761069691000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.6.647.34542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1592\/phco.21.6.647.34542"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.6.647.34542","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}